• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease.

作者信息

Pegoraro Francesco, Maniscalco Valerio, Peyronel Francesco, Westenend Pieter J, Hendriksz Tadek R, Roperto Rosa M, Palumbo Alessandro A, Sieni Elena, Romagnani Paola, van Bommel Eric F H, Vaglio Augusto

机构信息

Department of Health Sciences, University of Firenze, Florence, Italy.

Nephrology Unit, University Hospital, Parma, Italy.

出版信息

Blood. 2020 May 28;135(22):1994-1997. doi: 10.1182/blood.2019004478.

DOI:10.1182/blood.2019004478
PMID:32299103
Abstract
摘要

相似文献

1
Long-term follow-up of mTOR inhibition for Erdheim-Chester disease.mTOR 抑制剂治疗 Erdheim-Chester 病的长期随访
Blood. 2020 May 28;135(22):1994-1997. doi: 10.1182/blood.2019004478.
2
Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.MEK抑制剂考比替尼治疗野生型BRAF Erdheim-Chester病的疗效。
Br J Haematol. 2018 Jan;180(1):150-153. doi: 10.1111/bjh.14284. Epub 2016 Oct 6.
3
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).针对54例 Erdheim-Chester病患者的靶向治疗，包括中断治疗后的随访（LOVE研究）。
Blood. 2017 Sep 14;130(11):1377-1380. doi: 10.1182/blood-2017-03-771873. Epub 2017 Jun 30.
4
Significant response to dabrafenib in a patient with Erdheim-Chester disease with BRAFV600E mutation.达拉非尼对一名患有BRAFV600E突变的Erdheim-Chester病患者有显著疗效。
Pol Arch Intern Med. 2018 Jun 29;128(6):386-388. doi: 10.20452/pamw.4284.
5
A 72-year old female with multiple supra- and infratentorial dural masses.一名72岁女性，患有多个幕上和幕下硬脑膜肿块。
Brain Pathol. 2018 Nov;28(6):1023-1024. doi: 10.1111/bpa.12666.
6
Hypoalphalipoproteinemia and BRAF Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.低α脂蛋白血症和 BRAF 突变是 Erdheim-Chester 病主动脉浸润的主要预测因子。
Arterioscler Thromb Vasc Biol. 2018 Aug;38(8):1913-1925. doi: 10.1161/ATVBAHA.118.310803.
7
Acute Pancreatitis From Treatment With BRAF Inhibitors in Erdheim-Chester Disease: A Report From 2 Tertiary Referral Centers.Erdheim-Chester病中BRAF抑制剂治疗所致急性胰腺炎：来自两家三级转诊中心的报告
Pancreas. 2021 Jan 1;50(1):e6-e8. doi: 10.1097/MPA.0000000000001704.
8
Erdheim-Chester disease harboring the BRAF V600E mutation.携带BRAF V600E突变的 Erdheim-Chester 病。
J Clin Oncol. 2012 Nov 10;30(32):e331-2. doi: 10.1200/JCO.2012.43.2260. Epub 2012 Sep 24.
9
Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF mutation. Erdheim-Chester 病（ECD）的腹部受累：MRI 和 CT 影像学表现及其与 BRAF 突变的关系。
Eur Radiol. 2018 Sep;28(9):3751-3759. doi: 10.1007/s00330-018-5326-1. Epub 2018 Mar 19.
10
Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both and mutations.达拉非尼治疗后 Erdheim-Chester 病再次激活，伴 和 突变，使用曲美替尼治疗。
Blood. 2017 Feb 16;129(7):879-882. doi: 10.1182/blood-2016-09-740217. Epub 2016 Dec 9.

引用本文的文献

1
MEK inhibitors are effective in Erdheim-Chester disease regardless of MAPK pathway mutations.无论MAPK途径是否发生突变，MEK抑制剂对 Erdheim-Chester 病均有效。
Leukemia. 2025 Jun;39(6):1540-1542. doi: 10.1038/s41375-025-02614-6. Epub 2025 Apr 23.
2
Treatment holidays in patients with Erdheim-Chester disease receiving vemurafenib: a prospective pilot study.接受维莫非尼治疗的 Erdheim-Chester 病患者的治疗假期：一项前瞻性试点研究。
Blood Adv. 2025 May 13;9(9):2119-2121. doi: 10.1182/bloodadvances.2024015399.
3
The effect of methylation on the let-7-BCL2L1-BCL2 axis and the potential use of hypomethylating and BH3 mimetic drugs in histiocytic neoplasms.
甲基化对let-7-BCL2L1-BCL2轴的影响以及低甲基化和BH3模拟药物在组织细胞肿瘤中的潜在应用。
Leukemia. 2025 Feb;39(2):516-519. doi: 10.1038/s41375-024-02459-5. Epub 2024 Nov 8.
4
Current State of Targeted Therapy in Adult Langerhans Cell Histiocytosis and Erdheim-Chester Disease.成人朗格汉斯细胞组织细胞增生症和 Erdheim-Chester 病的靶向治疗现状。
Target Oncol. 2024 Sep;19(5):691-703. doi: 10.1007/s11523-024-01080-x. Epub 2024 Jul 11.
5
Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans Cell Histiocytosis).混合性组织细胞增多症（厄尔德海姆-切斯特病和朗格汉斯细胞组织细胞增多症）的长期结局和预后
EClinicalMedicine. 2024 May 27;73:102658. doi: 10.1016/j.eclinm.2024.102658. eCollection 2024 Jul.
6
Case report: Targeted treatment strategies for Erdheim-Chester disease.病例报告： Erdheim-Chester病的靶向治疗策略
Front Oncol. 2024 Mar 14;14:1305518. doi: 10.3389/fonc.2024.1305518. eCollection 2024.
7
[Mutation pedigree and treatment selection of Erdheim-Chester disease].[ Erdheim-Chester病的突变谱系与治疗选择 ]
Zhonghua Xue Ye Xue Za Zhi. 2023 Oct 14;44(10):876-880. doi: 10.3760/cma.j.issn.0253-2727.2023.10.019.
8
Erdheim-Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib.NRAS 基因内部新重复导致的 Erdheim-Chester 病：对考比替尼靶向治疗的反应。
Int J Mol Sci. 2023 Oct 23;24(20):15467. doi: 10.3390/ijms242015467.
9
Childhood-onset Erdheim-Chester disease in the molecular era: clinical phenotypes and long-term outcomes of 21 patients.分子时代儿童发病的 Erdheim-Chester 病：21 例患者的临床表型和长期结局。
Blood. 2023 Sep 28;142(13):1167-1171. doi: 10.1182/blood.2023020569.
10
H syndrome mimicking Erdheim Chester disease: new entity and therapeutic perspectives.模仿 Erdheim-Chester 病的 H 综合征：新实体与治疗前景
Haematologica. 2023 Aug 1;108(8):2255-2260. doi: 10.3324/haematol.2022.282040.